Cresset Asset Management LLC Has $1.36 Million Stock Position in Charles River Laboratories International, Inc. $CRL

Cresset Asset Management LLC boosted its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 57.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 8,703 shares of the medical research company’s stock after purchasing an additional 3,173 shares during the period. Cresset Asset Management LLC’s holdings in Charles River Laboratories International were worth $1,362,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Hantz Financial Services Inc. increased its holdings in shares of Charles River Laboratories International by 11.2% during the third quarter. Hantz Financial Services Inc. now owns 793 shares of the medical research company’s stock worth $124,000 after buying an additional 80 shares in the last quarter. Rothschild Investment LLC boosted its holdings in shares of Charles River Laboratories International by 82.4% in the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock worth $29,000 after acquiring an additional 84 shares in the last quarter. Patriot Financial Group Insurance Agency LLC grew its position in Charles River Laboratories International by 4.2% during the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 2,120 shares of the medical research company’s stock worth $332,000 after acquiring an additional 85 shares during the last quarter. Resona Asset Management Co. Ltd. grew its position in Charles River Laboratories International by 17.5% during the 3rd quarter. Resona Asset Management Co. Ltd. now owns 584 shares of the medical research company’s stock worth $86,000 after acquiring an additional 87 shares during the last quarter. Finally, EverSource Wealth Advisors LLC increased its holdings in Charles River Laboratories International by 51.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 308 shares of the medical research company’s stock valued at $48,000 after purchasing an additional 104 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have commented on CRL. Mizuho reduced their price objective on Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating on the stock in a research note on Friday, February 20th. Bank of America raised Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price target for the company in a report on Monday, December 15th. Wall Street Zen downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Argus set a $200.00 price objective on shares of Charles River Laboratories International in a report on Monday, November 17th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Charles River Laboratories International in a research note on Wednesday, January 21st. Ten research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $203.57.

Charles River Laboratories International Price Performance

Charles River Laboratories International stock opened at $176.88 on Tuesday. The business’s 50-day simple moving average is $194.78 and its 200 day simple moving average is $181.19. The stock has a market cap of $8.71 billion, a price-to-earnings ratio of -59.75, a P/E/G ratio of 2.98 and a beta of 1.64. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $228.88. The company has a quick ratio of 1.02, a current ratio of 1.29 and a debt-to-equity ratio of 0.67.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, February 18th. The medical research company reported $2.39 earnings per share for the quarter, topping the consensus estimate of $2.33 by $0.06. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The firm had revenue of $994.23 million during the quarter, compared to analysts’ expectations of $986.98 million. During the same period in the previous year, the business posted $2.66 EPS. The company’s quarterly revenue was down .8% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. As a group, research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.